Hemab Therapeutics adds Keli Walbert to board and audit committee

Hemab Therapeutics Holdings, Inc. reported in a Form 8-K dated September 24, 2026 that its board elected Keli Walbert as a new director. The election followed a recommendation from the Nominating and Corporate Governance Committee, and Walbert's appointment took effect immediately.¹

Walbert has been placed in the board's Class I director group, a seat that runs until the 2027 annual meeting of stockholders, and continuing after that until a successor is duly elected and qualified or until her earlier death, resignation, or removal.¹ She was also named to the company's Audit Committee.¹

The filing states there were no side arrangements tied to her appointment: there are no arrangements or understandings between Walbert and any other persons pursuant to which she was elected, she has no family relationships with any of the company's directors or executive officers, and there are no related-party transactions with the company requiring disclosure under Item 404(a) of Regulation S-K.¹

On compensation, Walbert will receive an option to purchase 36,000 shares of common stock at an exercise price equal to the closing price on the September 24, 2026 grant date, vesting monthly in equal installments over three years, contingent on her continued service.¹ That vesting would accelerate in full if the company undergoes a change in control.¹ She will also receive annual cash pay of $40,000 for board service and an additional $10,000 for Audit Committee membership, plus annual equity grants under the company's non-employee director policy and reimbursement for board-related travel expenses.¹

Walbert will also sign the company's standard indemnification agreement, the same form filed as an exhibit to Hemab's Form S-1 registration statement in April 2026.¹